to the moon‌[龇牙] ‌_老虎社区_美港股上老虎

boluo613
2022-11-18

to the moon‌[龇牙] ‌

Provention Bio's type 1 diabetes med teplizumab wins FDA approval

The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the

Provention Bio's type 1 diabetes med teplizumab wins FDA approval

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":667606941,"tweetId":"667606941","gmtCreate":1668739138383,"gmtModify":1668739140289,"author":{"id":3569806649777366,"idStr":"3569806649777366","authorId":3569806649777366,"authorIdStr":"3569806649777366","name":"boluo613","avatar":"https://static.tigerbbs.com/76878c45deee1566c2a4439d15dcd0b5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>to the moon‌<a href=\"\">[龇牙]&nbsp;</a>‌</p></body></html>","htmlText":"<html><head></head><body><p>to the moon‌<a href=\"\">[龇牙]&nbsp;</a>‌</p></body></html>","text":"to the moon‌[龇牙] ‌","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/667606941","repostId":2284745607,"repostType":2,"repost":{"id":"2284745607","kind":"highlight","pubTimestamp":1668726089,"share":"https://www.laohu8.com/m/news/2284745607?lang=&edition=full","pubTime":"2022-11-18 07:01","market":"us","language":"en","title":"Provention Bio's type 1 diabetes med teplizumab wins FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2284745607","media":"seekingalpha","summary":"The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the","content":"<html><body> <ul> <li>The US FDA has granted approval to Provention Bio (<span>NASDAQ:PRVB</span>) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D).</li> <li>The first-in-class medicine is given via intravenous infusion daily for 14 consecutive days.</li> <li>The therapy works by binding to specific immune system cells. It may also deactivate the immune cells that attack insulin-producing cells, while increasing the amount of cells that can moderate an immune response.</li> <li>Approval was based on the results of a placebo-controlled trial that showed over a median follow-up of 51 months, 45% of patients who received Tzield were later diagnosed with stage 3 T1D, compared to 72% of those on a placebo.</li> <li>Provention Bio (PRVB) shares soared earlier in November after the FDA issued proposed labeling for teplizumab.</li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Provention Bio's type 1 diabetes med teplizumab wins FDA approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProvention Bio's type 1 diabetes med teplizumab wins FDA approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-18 07:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3909501-provention-bio-type-1-diabetes-med-teplizumab-wins-fda-approval><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D). The first-in-class medicine is given via intravenous ...</p>\n\n<a href=\"https://seekingalpha.com/news/3909501-provention-bio-type-1-diabetes-med-teplizumab-wins-fda-approval\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/810721154/image_810721154.jpg","relate_stocks":{"PRVB":"Provention Bio, Inc","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3909501-provention-bio-type-1-diabetes-med-teplizumab-wins-fda-approval","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2284745607","content_text":"The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D). The first-in-class medicine is given via intravenous infusion daily for 14 consecutive days. The therapy works by binding to specific immune system cells. It may also deactivate the immune cells that attack insulin-producing cells, while increasing the amount of cells that can moderate an immune response. Approval was based on the results of a placebo-controlled trial that showed over a median follow-up of 51 months, 45% of patients who received Tzield were later diagnosed with stage 3 T1D, compared to 72% of those on a placebo. Provention Bio (PRVB) shares soared earlier in November after the FDA issued proposed labeling for teplizumab.","news_type":1},"isVote":1,"tweetType":1,"viewCount":441,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}